JP2016504307A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504307A5
JP2016504307A5 JP2015546492A JP2015546492A JP2016504307A5 JP 2016504307 A5 JP2016504307 A5 JP 2016504307A5 JP 2015546492 A JP2015546492 A JP 2015546492A JP 2015546492 A JP2015546492 A JP 2015546492A JP 2016504307 A5 JP2016504307 A5 JP 2016504307A5
Authority
JP
Japan
Prior art keywords
composition
telomerase inhibitor
individual
item
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015546492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504307A (ja
JP6433911B2 (ja
Filing date
Publication date
Priority claimed from US13/841,711 external-priority patent/US9375485B2/en
Application filed filed Critical
Priority claimed from PCT/US2013/070437 external-priority patent/WO2014088785A1/en
Publication of JP2016504307A publication Critical patent/JP2016504307A/ja
Publication of JP2016504307A5 publication Critical patent/JP2016504307A5/ja
Application granted granted Critical
Publication of JP6433911B2 publication Critical patent/JP6433911B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015546492A 2012-12-07 2013-11-15 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用 Active JP6433911B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261734941P 2012-12-07 2012-12-07
US61/734,941 2012-12-07
US201361799069P 2013-03-15 2013-03-15
US13/841,711 US9375485B2 (en) 2012-12-07 2013-03-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US61/799,069 2013-03-15
US13/841,711 2013-03-15
US201361900347P 2013-11-05 2013-11-05
US61/900,347 2013-11-05
PCT/US2013/070437 WO2014088785A1 (en) 2012-12-07 2013-11-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017232485A Division JP6998191B2 (ja) 2012-12-07 2017-12-04 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用

Publications (3)

Publication Number Publication Date
JP2016504307A JP2016504307A (ja) 2016-02-12
JP2016504307A5 true JP2016504307A5 (cg-RX-API-DMAC7.html) 2016-12-22
JP6433911B2 JP6433911B2 (ja) 2018-12-05

Family

ID=50883867

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015546492A Active JP6433911B2 (ja) 2012-12-07 2013-11-15 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用
JP2017232485A Active JP6998191B2 (ja) 2012-12-07 2017-12-04 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用
JP2019231517A Pending JP2020041001A (ja) 2012-12-07 2019-12-23 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用
JP2022000951A Active JP7288098B2 (ja) 2012-12-07 2022-01-06 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用
JP2022163881A Withdrawn JP2022179684A (ja) 2012-12-07 2022-10-12 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用
JP2025080100A Pending JP2025109842A (ja) 2012-12-07 2025-05-12 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017232485A Active JP6998191B2 (ja) 2012-12-07 2017-12-04 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用
JP2019231517A Pending JP2020041001A (ja) 2012-12-07 2019-12-23 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用
JP2022000951A Active JP7288098B2 (ja) 2012-12-07 2022-01-06 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用
JP2022163881A Withdrawn JP2022179684A (ja) 2012-12-07 2022-10-12 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用
JP2025080100A Pending JP2025109842A (ja) 2012-12-07 2025-05-12 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用

Country Status (36)

Country Link
EP (5) EP3646876B1 (cg-RX-API-DMAC7.html)
JP (6) JP6433911B2 (cg-RX-API-DMAC7.html)
KR (4) KR20230028590A (cg-RX-API-DMAC7.html)
CN (2) CN111617252A (cg-RX-API-DMAC7.html)
AP (1) AP2015008504A0 (cg-RX-API-DMAC7.html)
AU (4) AU2013356533B2 (cg-RX-API-DMAC7.html)
CA (2) CA3188494A1 (cg-RX-API-DMAC7.html)
CL (2) CL2015001530A1 (cg-RX-API-DMAC7.html)
CY (3) CY1122169T1 (cg-RX-API-DMAC7.html)
DK (3) DK3456333T3 (cg-RX-API-DMAC7.html)
EA (1) EA032973B1 (cg-RX-API-DMAC7.html)
ES (3) ES2982897T3 (cg-RX-API-DMAC7.html)
FI (2) FI3646876T3 (cg-RX-API-DMAC7.html)
FR (1) FR25C1016I2 (cg-RX-API-DMAC7.html)
HK (1) HK1210940A1 (cg-RX-API-DMAC7.html)
HR (3) HRP20240624T1 (cg-RX-API-DMAC7.html)
HU (4) HUE066402T2 (cg-RX-API-DMAC7.html)
IL (3) IL280144B2 (cg-RX-API-DMAC7.html)
LT (4) LT3646876T (cg-RX-API-DMAC7.html)
MA (2) MA38193B1 (cg-RX-API-DMAC7.html)
ME (1) ME03538B (cg-RX-API-DMAC7.html)
MX (3) MX372753B (cg-RX-API-DMAC7.html)
MY (2) MY180634A (cg-RX-API-DMAC7.html)
NL (1) NL301326I2 (cg-RX-API-DMAC7.html)
NZ (1) NZ708920A (cg-RX-API-DMAC7.html)
PH (2) PH12019501008A1 (cg-RX-API-DMAC7.html)
PL (3) PL2928477T3 (cg-RX-API-DMAC7.html)
PT (3) PT3456333T (cg-RX-API-DMAC7.html)
RS (2) RS60401B1 (cg-RX-API-DMAC7.html)
SG (3) SG11201504383TA (cg-RX-API-DMAC7.html)
SI (3) SI3456333T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201900567T1 (cg-RX-API-DMAC7.html)
TN (1) TN2015000249A1 (cg-RX-API-DMAC7.html)
UA (3) UA126015C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014088785A1 (cg-RX-API-DMAC7.html)
ZA (3) ZA201504124B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61840B1 (sr) 2004-07-02 2021-06-30 Geron Corp Sinteza zaštićenih 3'-amino 5'-fosforamidit nukleozidnih monomera
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
MX376856B (es) 2013-08-07 2025-03-07 Incyte Holdings Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
US11123359B2 (en) * 2013-11-06 2021-09-21 Mayo Foundation For Medical Education And Research Methods and materials for treating hematological malignancies
JP2018513127A (ja) 2015-04-23 2018-05-24 ジェロン・コーポレーションGeron Corporation 多価カチオン塩組成物を用いたポリヌクレオチド調製方法
EP3318276A1 (en) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
EP3658156B1 (en) * 2017-07-28 2026-03-25 Geron Corporation Telomerase inhibitor for use in treating a myelodysplastic syndrome
IL319432A (en) * 2018-04-30 2025-05-01 Kartos Therapeutics Inc Methods of treating cancer
US12268681B2 (en) 2018-05-25 2025-04-08 Kartos Therapeutics, Inc. Methods of treating myeloproliferative neoplasms
CN112770783B (zh) * 2018-07-31 2025-02-25 美国杰龙生物医药公司 鉴定可能从端粒酶抑制剂治疗中受益的患者的方法
CN113631719A (zh) 2018-11-29 2021-11-09 美国杰龙生物医药公司 治疗骨髓增生异常综合征的方法
JP7767279B2 (ja) 2019-11-04 2025-11-11 ジェロン・コーポレーション 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用
JP2021157248A (ja) * 2020-03-25 2021-10-07 パイオニア株式会社 状況出力装置
CA3181682A1 (en) * 2020-07-17 2022-01-20 Anil Kapur Subcutaneous telomerase inhibitor compositions and methods for using same
JP2024504367A (ja) * 2021-01-22 2024-01-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療及び改善するための方法
WO2024259369A1 (en) * 2023-06-14 2024-12-19 Rarecells Inc. Compositions targeting giant cells in blood disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
EP0951568A1 (en) 1996-12-20 1999-10-27 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
WO2004070008A2 (en) * 2003-01-31 2004-08-19 Au Jessie L-S Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
CN1244592C (zh) * 2003-07-11 2006-03-08 暨南大学 抑制白血病细胞端粒酶活性的反义核酸及其应用
DK3342425T3 (da) 2003-09-09 2020-03-16 Geron Corp Modificerede oligonukleotider til inhibering af telomerase
US20050282893A1 (en) * 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
RS61840B1 (sr) 2004-07-02 2021-06-30 Geron Corp Sinteza zaštićenih 3'-amino 5'-fosforamidit nukleozidnih monomera
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
WO2006113426A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
EP1876893B1 (en) 2005-04-15 2012-04-11 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
EP4600359A2 (en) 2006-10-30 2025-08-13 Geron Corporation Combined telomerase inhibitor and gemcitabine for the treatment of cancer
CN101220044B (zh) * 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途

Similar Documents

Publication Publication Date Title
ES2789176T3 (es) Uso del inhibidor de la telomerasa imetelstat para el tratamiento del síndrome mielodisplásico
US20230183704A1 (en) Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
JP7654761B2 (ja) 骨髄異形成症候群の治療方法
JP2015501329A5 (cg-RX-API-DMAC7.html)
Manjunath et al. Adenosine and adenosine receptors: Newer therapeutic perspective
JP2025061603A (ja) 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用
JP2023500326A5 (cg-RX-API-DMAC7.html)
CN112533605A (zh) 用于治疗癌症的组合疗法
HK40036832A (en) Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
HK40018627A (en) The telomerase inhibitor imetelstat for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
HK1212226B (en) Use of the telomerase inhibitor imetelstat for the treatment of myelofibrosis